Perceptive Informatics' Randomization Technologies Used In More Than 3,000 Clinical Trials For Improved Data Access And Faster Decision Making

Perceptive Informatics' Randomization Technologies Used In More Than 3,000 Clinical Trials For Improved Data Access And Faster Decision Making

BOSTON, Dec. 4, 2012  – Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ:PRXL), today announced that its ClinPhone® Randomization and Trial Supply Management (RTSM) technologies have been used in over 3,000 studies involving more than 289,000 sites and 1.7 million patients, helping pharmaceutical sponsors to achieve more efficient data collection, faster patient enrollment and more streamlined trial supply management.

"The pressures on the pharmaceutical industry to improve the productivity of the drug development process are greater than ever before, and our goal is to enable clients to successfully meet those challenges by maximizing the value of their clinical trial technologies," said Nick Richards, Vice President, Product Management, Perceptive Informatics. "Our deep experience is creating significant competitive advantage for us and, going forward, we remain committed to the continuous improvement of our offering based upon this expertise."

Built on the leading-edge PAREXEL MyTrials™ platform  and combined with PAREXEL's extensive medical and clinical expertise, ClinPhone RTSM technologies offer validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities and real-time supply reporting. The solutions provide sophisticated reporting to monitor trial management performance, trending and forecasting information, and in-depth data analysis. Clinical trials worldwide can be supported in multiple languages through the solutions, which provide secure access, detailed audit trails, transaction logging and compliance with FDA 21 CFR Part 11.

In addition to the ClinPhone RTSM solution, the comprehensive eClinical portfolio from Perceptive Informatics includes Electonic Data Capture (EDC), Clinical Trial Management Systems (CTMS) and Medical Imaging as well as Electronic Patient Reported Outcomes (ePRO). The Perceptive eClinical Suite provides convergence among systems for real-time data interchange and enables diverse applications to work synergistically.

For more information about the ClinPhone RTSM technologies from Perceptive Informatics, visit

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO).  The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 13,330 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 as filed with the SEC on November 8, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.

The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.


Diana Martin, Vice President Corporate Communications 

Kim Leadley/Sarah Bruckner          

PAREXEL International  

PAN Communications

Tel: + 1 781-434-5516 

Tel: + 1 617-502-4300

Email: [email protected] 

Email: [email protected]

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.